CXM vs NVDA

CXM exhibits a stable but mediocre financial health profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided. Despite consistent earnings beats and a clean balance sheet (Debt/Equity 0.08), the stock is trading at a significant premium to its Graham Number ($2.20) and Intrinsic Value ($0.63). Severe price erosion across all timeframes, combined with aggressive insider selling and a -90% YoY earnings collapse, outweighs the optimistic forward P/E and PEG ratio.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.